Provided by Tiger Trade Technology Pte. Ltd.

IO Biotech, Inc.

0.4801
+0.2725131.26%
Pre-market: 0.4412-0.0389-8.10%09:07 EST
Volume:473.91M
Turnover:190.44M
Market Cap:34.54M
PE:-0.36
High:0.5792
Open:0.2464
Low:0.2302
Close:0.2076
52wk High:2.79
52wk Low:0.2053
Shares:71.95M
Float Shares:31.16M
Volume Ratio:61.50
T/O Rate:1520.89%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-1.3356
EPS(LYR):-1.4494
ROE:-240.48%
ROA:-88.58%
PB:37.92
PE(LYR):-0.33

Loading ...

IO Biotech Inc - to Reduce Workforce by About 50%

THOMSON REUTERS
·
Sep 29, 2025

IO Biotech Provides Update Following Pre-Bla Meeting With FDA

THOMSON REUTERS
·
Sep 29, 2025

IO Biotech Inc - Expects $1.0 Mln-$1.5 Mln Charge in Q3 2025

THOMSON REUTERS
·
Sep 29, 2025

IO Biotech Inc - Plans New Study for Cylembio in Melanoma

THOMSON REUTERS
·
Sep 29, 2025

IO Biotech Announces Late-Breaking Abstract in Advanced Melanoma Selected for Oral Presentation at ESMO Congress 2025

GlobeNewswire
·
Sep 23, 2025

IO Biotech Inc : Jefferies Cuts Target Price to $4 From $8

THOMSON REUTERS
·
Sep 09, 2025

IO Biotech Announces Participation in Upcoming Investor Conferences

GlobeNewswire
·
Sep 04, 2025

IO Biotech Inc reports results for the quarter ended June 30 - Earnings Summary

Reuters
·
Aug 15, 2025

IO Biotech Q2 EPS $(0.40) Misses $(0.35) Estimate

Benzinga
·
Aug 15, 2025

IO Biotech Q2 Pretax Profit USD -26.099 Million

THOMSON REUTERS
·
Aug 15, 2025

IO Biotech Inc - Expects That Co Will Have Sufficient Cash to Run Company Into Q1 of 2026

THOMSON REUTERS
·
Aug 15, 2025

IO Biotech Reports Second Quarter 2025 Financial Results and Provides Business Highlights

GlobeNewswire
·
Aug 15, 2025

IO Biotech Inc expected to post a loss of 36 cents a share - Earnings Preview

Reuters
·
Aug 12, 2025

BUZZ-U.S. STOCKS ON THE MOVE-Elf Beauty, Intel, Archer Aviation

Reuters
·
Aug 12, 2025

BUZZ-IO Biotech drops after cancer vaccine narrowly misses main goal of late-stage study

Reuters
·
Aug 11, 2025

IO Biotech Shares up 12.2% at $2.03 Premarket in Volatile Trading Shortly After Trading Halt

THOMSON REUTERS
·
Aug 11, 2025

IO Biotech Shares up 56.9% Premarket After Co Reports Late-Stage Data for Therapeutic Cancer Vaccine

THOMSON REUTERS
·
Aug 11, 2025

IO Biotech Announces Promising Results in Phase 3 Trial of Cylembio Plus KEYTRUDA for Advanced Melanoma, Plans FDA Meeting

Reuters
·
Aug 11, 2025

IO Biotech Inc - Cylembio Plus Keytruda Well Tolerated With No New Safety Signals

THOMSON REUTERS
·
Aug 11, 2025

IO Biotech Inc - Plans FDA Meeting This Fall for Regulatory Submission

THOMSON REUTERS
·
Aug 11, 2025